Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CASP3 | P42574 | 1/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.34 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.34 |
| ▸ | NPC1 | O15118 | 1/20 | 0.33 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | APEX1 | P27695 | 1/20 | 0.33 |
| ▸ | PARP1 | P09874 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.32 |
| ▸ | CA1 | P00915 | 1/20 | 0.32 |
| ▸ | CA2 | P00918 | 1/20 | 0.32 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.32 |
| ▸ | DPP4 | P27487 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL949485 | 1.00 | CASP3 (0.39) | CASP3HSD17B10ROCK2NPC1EPHX2 | |
| SCHEMBL644711 | 0.82 | ACE (0.40) | CASP3HSD17B10ROCK2NPC1PARP1 | |
| SCHEMBL949749 | 0.82 | ACE (0.40) | CASP3HSD17B10ROCK2NPC1PARP1 | |
| SCHEMBL10565831 | 0.82 | ACE (0.44) | CASP3HSD17B10ROCK2NPC1EPHX2 | |
| SCHEMBL3731407 | 0.81 | LTA4H (0.36) | CASP3CYP3A4TSHRTDP1MAPT | |
| SCHEMBL13260166 | 0.81 | LTA4H (0.36) | CASP3CYP3A4TSHRTDP1MAPT | |
| SCHEMBL10248857 | 0.79 | CASP3 (0.38) | CASP3HSD17B10ROCK2NPC1EPHX2 | |
| SCHEMBL10201273 | 0.79 | CASP3 (0.38) | CASP3HSD17B10ROCK2NPC1EPHX2 | |
| SCHEMBL8318471 | 0.78 | ACE (0.44) | CYP3A4TSHRTDP1MAPTAPEX1 | |
| SCHEMBL645595 | 0.78 | ACE (0.44) | CYP3A4TSHRTDP1MAPTAPEX1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2005003134-A1 | A NOVEL PROCESS FOR THE PREPARATION OF CILAZAPRIL | HETERO DRUGS LIMITED (IN) | 2005-01-13 | — | — | WO | claimed |
| US-20120238749-A1 | INHIBITORS OF INTERLEUKIN-1 BETA CONVERTING ENZYME | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-09-20 | — | — | US | disclosed |
| US-20110178069-A1 | INHIBITORS OF INTERLEUKIN-1 BETA CONVERTING ENZYME | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2011-07-21 | — | — | US | disclosed |
| EP-2295442-A2 | Inhibitors of interleukin-1beta converting enzyme | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2011-03-16 | — | — | EP | disclosed |
| US-20110015371-A1 | Inhibitors of interleukin-1 beta converting enzyme | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2011-01-20 | — | — | US | disclosed |
| US-7790713-B2 | Inhibitors of interleukin-1β converting enzyme | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2010-09-07 | — | — | US | disclosed |
| US-7772366-B2 | Inhibitors of interleukin-1β converting enzyme | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2010-08-10 | — | — | US | disclosed |
| EP-2083014-A2 | Inhibitors of interleukin-1ß converting enzyme | Vertex Pharmceuticals Incorporated (US) | 2009-07-29 | — | — | EP | disclosed |
| US-20080070953-A1 | Inhibitors of interleukin-1 beta converting enzyme | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2008-03-20 | — | — | US | disclosed |
| US-20080039449-A1 | Inhibitors of interleukin-1beta converting enzyme | BATCHELOR MARK J | 2008-02-14 | — | — | US | disclosed |
| WO-2005003134-A1 | A NOVEL PROCESS FOR THE PREPARATION OF CILAZAPRIL | HETERO DRUGS LIMITED (IN) | 2005-01-13 | — | — | WO | disclosed |
| WO-2005003134-A1 | A NOVEL PROCESS FOR THE PREPARATION OF CILAZAPRIL | HETERO DRUGS LIMITED (IN) | 2005-01-13 | — | — | WO | disclosed |
| US-20030225269-A1 | Inhibitors of interleukin-1beta converting enzyme | VERTEX PHARMACEUTICALS INCORPORATED | 2003-12-04 | — | — | US | disclosed |
| US-20020099042-A1 | Inhibitors of interleukin-1 beta converting enzyme | VERTEX PHARMACEUTICALS INCORPORATED | 2002-07-25 | — | — | US | disclosed |
| US-6423840-B1 | FORMING N-ACYLAMINO COMPOUND | VERTEX PHARMACEUTICALS INCORPORATED | 2002-07-23 | — | — | US | disclosed |
| US-6420522-B1 | ENZYME INHIBITORS | VERTEX PHARMACEUTICALS INCORPORATED | 2002-07-16 | — | — | US | disclosed |
| US-6258948-B1 | AN N-ACYLAMINO COMPOUND; ANTIINFLAMMATORY AGENTS, AUTOIMMUNE DISEASES | VERTEX PHARMACEUTICALS, INCORPORATED | 2001-07-10 | — | — | US | disclosed |
| US-6204261-B1 | Inhibitors of interleukin-1β Converting enzyme inhibitors | VERTEX PHARMACEUTICALS INCORPORATED | 2001-03-20 | — | — | US | disclosed |
| US-4782149-A | INHIBITORS OF ANGIOTENSIN CONVERTING ENZYME, HYPOTENSIVES | HOFFMAN-LA ROCHE INC. (US) | 1988-11-01 | — | — | US | disclosed |
| US-4757069-A | Hypotensive agents | HOFFMANN-LA ROCHE INC. (US) | 1988-07-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080070953-A1 | Inhibitors of interleukin-1 beta converting enzyme | IL1B, IL1A, IL1R1 | CASP3 542/4885HSD17B10 816/4885ROCK2 1830/4885 |
| US-20020099042-A1 | Inhibitors of interleukin-1 beta converting enzyme | IL1B, IL1A, IL1RN | CASP3 555/4885HSD17B10 820/4885ROCK2 1780/4885 |
| US-20110178069-A1 | INHIBITORS OF INTERLEUKIN-1 BETA CONVERTING ENZYME | IL1A, IFNAR1, IL1B | CASP3 85/4885HSD17B10 1135/4885ROCK2 2383/4885 |
| US-20080039449-A1 | Inhibitors of interleukin-1beta converting enzyme | IL1A, IL1B, IFNAR1 | CASP3 67/4885HSD17B10 925/4885ROCK2 2566/4885 |
| US-20110015371-A1 | Inhibitors of interleukin-1 beta converting enzyme | IL1B, IL1A, IL1R1 | CASP3 542/4885HSD17B10 816/4885ROCK2 1830/4885 |
| US-20030225269-A1 | Inhibitors of interleukin-1beta converting enzyme | IL1A, APAF1, IL1B | CASP3 75/4885HSD17B10 924/4885ROCK2 2749/4885 |
| US-20120238749-A1 | INHIBITORS OF INTERLEUKIN-1 BETA CONVERTING ENZYME | IL1B, IL1A, IL1R1 | CASP3 542/4885HSD17B10 816/4885ROCK2 1830/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.